Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib + Denosumab in Bone-Predominant RR-DTC
NCT03732495Phase 2Unknown
- Sponsor
- Centre Léon Bérard
- Start
- Jul 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib in differentiated thyroid carcinoma (DTC), sponsored by Centre Léon Bérard. Status: unknown.
02
Drugs
lenvatinib
03
Conditions
differentiated thyroid carcinoma (DTC)
Beyond the preview
Go deeper on NCT03732495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03732495.